Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • clemcaldwell clemcaldwell May 22, 2013 2:35 PM Flag

    Bristol-Myers shares jump on ‘beginning of the end of cancer’

    "Nivolumab, now in Phase 3 testing and could win approval as early as next year.[Bristol-Myers's] current Phase 3 program is only the tip of the iceberg, The drug, which has proven effective with other medications in treating melanoma, could end up being expanded outside initial indications in lung cancer and renal cancer."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I imagine much of EXEL's recent weakness is do to progress in this area. The results are great and it's almost fire and forget. Targeted therapies and deep sequencing genetic based diagnostics should stack with these treatments but it could eat into EXEL revenues.

      • 2 Replies to wildbiftek
      • May I ask you an OT question? Do you think which direction in immunologic cancer therapy will be more promising: boosting immune system as a whole or telling immune system what markers to attack? Or combination of both? Frankly, I didn't see any "beginning of the end of cancer".

      • I'll take back some of what I said about immuno-therapies. There are notable issues w/ Ipi and AEs. Nivolumab also just doesn't work that well in Prostate cancer (onclive):

        "Slovin, who worked with three of the CRPC patients in the study, said she had hoped that “Maybe [the results with] PD-1 would be better than our work with ipilimumab.” Unfortunately, the prostate data were not positive. While objective response rates as high as 28%, 27%, and 18% were observed in patients with melanoma, renal cell carcinoma, and non–small cell lung cancer, respectively, no objective responses were observed in patients with prostate cancer."

        In indications where it does work though as in the case of advanced melanoma, the results make it seem like the standard of care going forward.

 
EXEL
5.73+0.19(+3.43%)Jul 31 4:00 PMEDT